Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie's choice for patients with relapsed refractory multiple myeloma

Expert Rev Hematol. 2022 Jun;15(6):473-475. doi: 10.1080/17474086.2022.2081147. Epub 2022 May 26.

Authors

James Davis¹, Mary McGann¹, Abigail Shockley¹, Hamza Hashmi¹

Affiliation

¹ Department of Malignant Hematology and Bone Marrow Transplant, Medical University of South Carolina, Charleston, South Carolina, USA.

PMID: 35603733
DOI: 10.1080/17474086.2022.2081147

No abstract available

Keywords: BCMA; CAR T; Myeloma; cilta-cel; ida-cel.

Publication types

Editorial

MeSH terms

B-Cell Maturation Antigen
Humans
Multiple Myeloma* / therapy
Receptors, Chimeric Antigen*

Substances

B-Cell Maturation Antigen
Receptors, Chimeric Antigen
idecabtagene vicleucel